WOODBRIDGE, ON, Oct. 8, 2014 /CNW/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that the United Stated Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Pivotal's U.S. Patent Application Serial Number 13/584,403 titled "Cholesterol Absorption Inhibitor and Omega-3 Fatty Acids for the Reduction of Cholesterol and for the Prevention or Reduction of Cardiovascular, Cardiac and Vascular Events." This application includes claims intended to protect VASCAZEN® and its formulation in conjunction with at least one azetidinone cholesterol absorption inhibitor. This notice constitutes allowance of the patent and impending issuance. The issued patent would have a term that expires no earlier than in 2032.
Receipt of the Notice of Allowance in this application is further recognition of the novel properties of VASCAZEN®'s formulation for the treatment of risk factors for cardiovascular disease, reduction of overall serum cholesterol levels, reduction in high blood pressure, increase in the HDL:LDL ratio, and reduction of triglycerides, particularly when utilized in combination with at least one azetidinone cholesterol absorption inhibitor.
"We are very excited that the USPTO has allowed claims that will protect our formulation in conjunction with a cholesterol absorption inhibitor. We believe that the recently allowed patents combining the key cholesterol lowering agents (Statins) and cholesterol absorption inhibitors with our unique Omega-3 fatty acid formulation could significantly benefit the management of cardiovascular patients going forward," said Dr. George Jackowski, Co-Founder and Chief Scientific Officer of Pivotal.
This application is part of an expanding patent portfolio for Pivotal protecting its unique formulation with three (3) patent applications now either issued or allowed with the USPTO and over seven (7) additional applications pending in the United States. Pivotal is also pursuing patent applications related to VASCAZEN®'s formulation in multiple jurisdictions outside the United States.
VASCAZEN® is currently available in the U.S. as a prescription only medical food specifically formulated for the dietary management of an Omega-3 deficiency in cardiovascular patients. VASCAZEN® is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series of both U.S. and foreign patents.
VASCAZEN® has been clinically shown in the VASCAZEN®-REVEAL Trial to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase of HDL without negative impact on the LDL-C lipid profile. The publication of the trial entitled "Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN®-REVEAL Trial" can be found in Molecular and Cellular Biochemistry (MCB), http://link.springer.com/article/10.1007/s11010-014-2132-1/fulltext.html.
VASCAZEN®'s results were achieved with a dose of 3 grams of EPA and DHA per day of a prescription grade, high purity, uniquely formulated Omega-3.
For more information about VASCAZEN® please visit www.vascazen.com.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics' lead product VASCAZEN® is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. OMAZEN® is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. OMAZEN® is a patented product available for sale and distribution in Canada. For more information about Pivotal visit www.pivotaltherapeutics.us.
The information contained in this document is as of October 8, 2014. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSE listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.
SOURCE: Pivotal Therapeutics Inc.
For further information: Company Contacts: Kristine DiMatteo, Communications and Public Relations Manager, Phone: 905-856-9797 ext. 231, E-Mail: [email protected]; Investor & Media Contact: Stephen Kilmer, President, Kilmer Lucas Inc., Phone: 647-872-4849, E-Mail: [email protected]